Guggenheim Capital LLC Has $2.69 Million Position in Exact Sciences Co. (NASDAQ:EXAS)

Guggenheim Capital LLC trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 26.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,658 shares of the medical research company’s stock after selling 13,943 shares during the quarter. Guggenheim Capital LLC’s holdings in Exact Sciences were worth $2,689,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in EXAS. Park Place Capital Corp grew its holdings in Exact Sciences by 189.2% during the 1st quarter. Park Place Capital Corp now owns 376 shares of the medical research company’s stock worth $25,000 after acquiring an additional 246 shares during the last quarter. Desjardins Global Asset Management Inc. lifted its position in shares of Exact Sciences by 42.2% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 549 shares of the medical research company’s stock worth $27,000 after purchasing an additional 163 shares during the period. True Wealth Design LLC acquired a new stake in shares of Exact Sciences during the fourth quarter worth $30,000. Assetmark Inc. acquired a new position in Exact Sciences in the fourth quarter valued at $31,000. Finally, TCI Wealth Advisors Inc. grew its holdings in Exact Sciences by 15,466.7% during the 1st quarter. TCI Wealth Advisors Inc. now owns 467 shares of the medical research company’s stock worth $32,000 after acquiring an additional 464 shares during the period. 89.13% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on EXAS shares. Bank of America boosted their target price on shares of Exact Sciences from $105.00 to $110.00 in a research report on Wednesday, August 2nd. Citigroup lifted their price objective on shares of Exact Sciences from $100.00 to $130.00 in a report on Thursday, June 22nd. Jefferies Financial Group raised their target price on Exact Sciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. Piper Sandler upped their price target on Exact Sciences from $80.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, August 8th. Finally, Robert W. Baird raised their price objective on Exact Sciences from $99.00 to $121.00 and gave the company an “outperform” rating in a research note on Wednesday, August 2nd. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

Exact Sciences Trading Up 3.7 %

NASDAQ:EXAS opened at $83.12 on Wednesday. Exact Sciences Co. has a 1 year low of $29.27 and a 1 year high of $100.77. The stock’s fifty day moving average price is $90.50 and its two-hundred day moving average price is $78.26. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 2.14. The company has a market cap of $15.02 billion, a P/E ratio of -34.21 and a beta of 1.42.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.05. The firm had revenue of $622.10 million for the quarter, compared to analysts’ expectations of $601.14 million. Exact Sciences had a negative net margin of 18.76% and a negative return on equity of 14.08%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.94) earnings per share. As a group, analysts expect that Exact Sciences Co. will post -1.9 EPS for the current year.

Insider Buying and Selling at Exact Sciences

In related news, CFO Jeffrey Thomas Elliott sold 30,210 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $82.92, for a total value of $2,505,013.20. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, CFO Jeffrey Thomas Elliott sold 30,210 shares of the stock in a transaction on Monday, August 21st. The stock was sold at an average price of $82.92, for a total value of $2,505,013.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel James Herriott sold 1,300 shares of the firm’s stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $90.00, for a total value of $117,000.00. Following the sale, the general counsel now owns 7,264 shares in the company, valued at approximately $653,760. The disclosure for this sale can be found here. Insiders have sold a total of 37,562 shares of company stock valued at $3,188,552 in the last 90 days. Corporate insiders own 1.30% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.